Tim Heise

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6389287/publications.pdf

Version: 2024-02-01

73 papers	4,576 citations	126907 33 h-index	102487 66 g-index
74 all docs	74 docs citations	74 times ranked	3388 citing authors

#	Article	IF	Citations
1	New Clamp-PID Algorithm for Automated Glucose Clamps Improves Clamp Quality. Journal of Diabetes Science and Technology, 2022, 16, 408-414.	2.2	3
2	Novel Drugs for Diabetes Therapy. Handbook of Experimental Pharmacology, 2022, , 1.	1.8	0
3	What is the value of faster acting prandial insulin? Focus on ultra rapid lispro. Diabetes, Obesity and Metabolism, 2022, 24, 1689-1701.	4.4	14
4	The majority of people with type <scp>1</scp> diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the <scp>GOLD</scp> randomized trial (<scp>GOLDâ€5</scp>). Diabetes, Obesity and Metabolism, 2021, 23, 619-630.	4.4	9
5	ADO09, a coâ€formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 961-970.	4.4	18
6	Cover Image, Volume 23, Issue 4. Diabetes, Obesity and Metabolism, 2021, 23, .	4.4	0
7	The future of insulin therapy. Diabetes Research and Clinical Practice, 2021, 175, 108820.	2.8	30
8	Basal Insulin Fc (BIF), A Novel Insulin Suited For Once Weekly Dosing For The Treatment of Patients With Diabetes Mellitus. Journal of the Endocrine Society, 2021, 5, A329-A329.	0.2	15
9	Diabetes Technology Meeting 2020. Journal of Diabetes Science and Technology, 2021, 15, 916-960.	2.2	1
10	Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity. Clinical Diabetes and Endocrinology, 2021, 7, 16.	2.7	8
11	Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus. Clinical Pharmacokinetics, 2021, , 1.	3.5	5
12	Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 803-820.	3.6	75
13	Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clinical Pharmacokinetics, 2020, 59, 155-172.	3.5	35
14	Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYLâ€1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2020, 22, 521-529.	4.4	9
15	Glucose management for exercise using continuous glucose monitoring (<scp>CGM</scp>) and intermittently scanned <scp>CGM</scp> (<scp>isCGM</scp>) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (<scp>EASD</scp>) and of the International Society for Pediatric and Adolescent Diabetes (<scp>ISPAD</scp>) endorsed by <scp>. Pediatric Diabetes, 2020, 21, 1375-1393.	2.9	46
16	Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus HumalogÂ® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study. Clinical Pharmacokinetics, 2020, 59, 1601-1610.	3.5	27
17	Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes, Obesity and Metabolism, 2020, 22, 1789-1798.	4.4	49
18	237-OR: Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes. Diabetes, 2020, 69, .	0.6	28

#	Article	IF	Citations
19	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. Diabetes Mellitus, 2020, 23, 140-160.	1.9	0
20	Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 179-188.	11.4	116
21	The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects. Clinical Pharmacokinetics, 2019, 58, 1497-1504.	3.5	23
22	Better glycaemic control with BioChaperone glargine lispro coâ€formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1570-1575.	4.4	5
23	Concentrated insulins in current clinical practice. Diabetes Research and Clinical Practice, 2019, 148, 93-101.	2.8	24
24	BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes, Obesity and Metabolism, 2019, 21, 1066-1070.	4.4	31
25	Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus. Clinical Pharmacokinetics, 2019, 58, 639-649.	3.5	8
26	Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2019, 21, 601-610.	4.4	28
27	Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2019, 21, 569-574.	4.4	13
28	Considering Blood Dilution improves the Precision of Continuous Whole Blood Glucose Measurements. Journal of Diabetes Science and Technology, 2019, 13, 751-755.	2.2	0
29	A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technology and Therapeutics, 2018, 20, 274-284.	4.4	88
30	Injecting without pressing a button: An exploratory study of a shieldâ€triggered injection mechanism. Diabetes, Obesity and Metabolism, 2018, 20, 1140-1147.	4.4	2
31	Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care, 2018, 41, 531-537.	8.6	86
32	Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies. Journal of Diabetes Science and Technology, 2018, 12, 356-363.	2.2	34
33	Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2018, 12, 145-151.	2.2	42
34	Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?. Diabetes, Obesity and Metabolism, 2018, 20, 2051-2056.	4.4	5
35	MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet, The, 2018, 391, 2607-2618.	13.7	227
36	Ultraâ€rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14â€day crossover treatment study in people with type 1 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2627-2632.	4.4	31

#	Article	IF	Citations
37	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. JAMA - Journal of the American Medical Association, 2017, 317, 379.	7.4	520
38	A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. Clinical Pharmacokinetics, 2017, 56, 551-559.	3.5	150
39	A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus. Drugs and Aging, 2017, 34, 29-38.	2.7	30
40	Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. Clinical Drug Investigation, 2017, 37, 503-509.	2.2	28
41	Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Current Medical Research and Opinion, 2017, 33, 1821-1831.	1.9	31
42	Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas. Clinical Drug Investigation, 2017, 37, 885-887.	2.2	0
43	Insulin degludec: <scp>L</scp>ower dayâ€toâ€day and withinâ€day variability in pharmacodynamic response compared with insulin glargine 300â€‰<scp>U</scp>/<scp>mL</scp> in type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1032-1039.	4.4	105
44	Improved Algorithm for Automated Glucose Clamps. Diabetes Technology and Therapeutics, 2017, 19, 124-130.	4.4	6
45	The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. Journal of the American Society of Hypertension, 2017, 11, 604-612.	2.3	69
46	Duration of action of two insulin glargine products, <scp>LY2963016</scp> insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 33-39.	4.4	22
47	Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes, Obesity and Metabolism, 2017, 19, 3-12.	4.4	84
48	A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Clinical Pharmacokinetics, 2017, 56, 339-354.	3.5	30
49	Pharmacological properties of fasterâ€acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, doubleâ€blind, crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 208-215.	4.4	67
50	Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus. Clinical Pharmacokinetics, 2017, 56, 649-660.	3.5	54
51	Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes, Obesity and Metabolism, 2016, 18, 962-972.	4.4	67
52	Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study). Journal of Diabetes Science and Technology, 2016, 10, 754-761.	2.2	18
53	Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes. Clinical Therapeutics, 2016, 38, 2265-2276.	2.5	71
54	Faster Onset and Greater Early Exposure and Glucose-Lowering Effect with Faster-Acting Insulin Aspart vs. Insulin Aspart: A Pooled Analysis in Subjects with Type 1 Diabetes. Canadian Journal of Diabetes, 2016, 40, S57.	0.8	4

#	Article	IF	Citations
55	Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics, 2016, 38, 2248-2264.e5.	2.5	43
56	Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. Diabetes Care, 2016, 39, 1486-1492.	8.6	127
57	Steady state is reached within 2â€“3 days of onceâ€daily administration of degludec, a basal insulin with an ultralong duration of action. Journal of Diabetes, 2016, 8, 132-138.	1.8	41
58	New Insulin Glargine 300 UnitsÂ·mLâ¯1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 UnitsÂ·mLâ¯1. Diabetes Care, 2015, 38, 637-643.	8.6	335
59	How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device. Journal of Diabetes Science and Technology, 2015, 9, 792-800.	2.2	48
60	Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1193-1201.	3.3	126
61	Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study. Clinical Therapeutics, 2015, 37, 793-803.	2.5	20
62	Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region. Clinical Drug Investigation, 2014, 34, 673-679.	2.2	28
63	A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. Clinical Pharmacokinetics, 2014, 53, 787-800.	3.5	187
64	Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus. Diabetes Therapy, 2014, 5, 255-265.	2.5	61
65	Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences. Endocrine Practice, 2014, 20, 75-83.	2.1	66
66	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2013, 4, 331-345.	2.5	102
67	Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes. Diabetes Care, 2012, 35, 2626-2630.	8.6	93
68	Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus. Diabetes Therapy, 2012, 3, 10.	2.5	46
69	Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, 1288-1290.	8.6	57
70	Getting closer to physiologic insulin secretion. Clinical Therapeutics, 2007, 29, S161-S165.	2.5	11
71	The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin: A prospective randomized pharmacodynamic study. Diabetes Care, 2005, 28, 2161-2169.	8.6	80
72	Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes. Diabetes, 2004, 53, 1614-1620.	0.6	570

#	Article	IF	Citations
73	Rapid and Long-Acting Analogues as an Approach to Improve Insulin Therapy: An Evidence-Based Medicine Assessment. Current Pharmaceutical Design, 2001, 7, 1303-1325.	1.9	44